<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80683</article-id><article-id pub-id-type="doi">10.7554/eLife.80683</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Mutant SF3B1 promotes malignancy in PDAC</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-282337"><name><surname>Simmler</surname><given-names>Patrik</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324268"><name><surname>Ioannidi</surname><given-names>Eleonora I</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282338"><name><surname>Mengis</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324269"><name><surname>Marquart</surname><given-names>Kim Fabiano</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324270"><name><surname>Asawa</surname><given-names>Simran</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282339"><name><surname>Van-Lehmann</surname><given-names>Kjong</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282340"><name><surname>Khales</surname><given-names>André</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282341"><name><surname>Thomas</surname><given-names>Tinu</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324271"><name><surname>Schwerdel</surname><given-names>Cornelia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-67223"><name><surname>Aceto</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20839"><name><surname>Rätsch</surname><given-names>Gunnar</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107092"><name><surname>Stoffel</surname><given-names>Markus</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1304-5817</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-281610"><name><surname>Schwank</surname><given-names>Gerald</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0767-2953</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biology</institution>, <institution>ETH Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff2"><institution content-type="dept">Institute of Pharmacology and Toxicology</institution>, <institution>University of Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff3"><institution content-type="dept">Center of Experimental Rheumatology</institution>, <institution>University Hospital of Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff4"><institution content-type="dept">Department of Computer Science</institution>, <institution>ETH Zurich</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-13853"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing editor</role><aff><institution>Fox Chase Cancer Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>schwank@pharma.uzh.ch</email> (GS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>10</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e80683</elocation-id><history><date date-type="received"><day>31</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Simmler et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Simmler et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80683-v1.pdf"/><abstract><p>The splicing factor SF3B1 is recurrently mutated in various tumors, including pancreatic ductal adenocarcinoma (PDAC). The impact of the hotspot mutation SF3B1<sup>K700E</sup> on the PDAC pathogenesis, however, remains elusive. Here, we demonstrate that Sf3b1<sup>K700E</sup> alone is insufficient to induce malignant transformation of the murine pancreas, but that it increases aggressiveness of PDAC if it co-occurs with mutated KRAS and p53. We further show that Sf3b1<sup>K700E</sup> already plays a role during early stages of pancreatic tumor progression and reduces the expression of TGF-β1-responsive epithelial-mesenchymal transition (EMT) genes. Moreover, we found that SF3B1<sup>K700E</sup> confers resistance to TGF-β1-induced cell death in pancreatic organoids and cell lines, partly mediated through aberrant splicing of <italic>Map3k7</italic>. Overall, our findings demonstrate that SF3B1<sup>K700E</sup> acts as an oncogenic driver in PDAC, and suggest that it promotes the progression of early stage tumors by impeding the cellular response to tumor suppressive effects of TGF-β.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>185293</award-id><principal-award-recipient><name><surname>Simmler</surname><given-names>Patrik</given-names></name><name><surname>Ioannidi</surname><given-names>Eleonora I</given-names></name><name><surname>Mengis</surname><given-names>Tamara</given-names></name><name><surname>Marquart</surname><given-names>Kim Fabiano</given-names></name><name><surname>Schwerdel</surname><given-names>Cornelia</given-names></name><name><surname>Schwank</surname><given-names>Gerald</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>176317</award-id><principal-award-recipient><name><surname>Simmler</surname><given-names>Patrik</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>101001652</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Personalized Health and Related Technologies at ETH Zurich</institution></institution-wrap></funding-source><award-id>PHRT-541</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>212183</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Swiss Cancer League</institution></institution-wrap></funding-source><award-id>KLS-4834-08-2019</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>ETH Lymphoma Challenge</institution></institution-wrap></funding-source><award-id>LC-02-22</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments were conducted in accordance with the Swiss Federal Veterinary Office (BVET) guidelines (license no. ZH055/17).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The RNA sequencing raw data of sorted murine cancer cells was deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE203339. Splice analysis of human cancers was performed on a previously published dataset, accessible at https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018 (Kahles et al., 2018).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Simmler P</collab><collab>et al</collab></person-group><year iso-8601-date="2022">2022</year><source>RNA-seq of sorted KPC Sf3b1-K700E murine PDAC cells</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203339">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203339</ext-link><comment>NCBI Gene Expression Omnibus, GSE203339</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Khales A</collab><collab>et al</collab></person-group><year iso-8601-date="2018">2018</year><source>Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients</source><ext-link ext-link-type="uri" xlink:href="https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018">https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018</ext-link><comment>GDC</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-80683-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>